BOUCHERVILLE, QC, Jan. 22,
2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL)
(TSXV: LSL.DB) ("the Corporation" or "LSL Pharma"), a Canadian
integrated pharmaceutical company, announced that it has granted an
aggregate of 625,000 share options (each, an "Option") to three new
officers and employees of the Corporation in accordance with the
Corporation's share option plan.
Each Option is exercisable for one common share in the capital
of LSL Pharma (a "Share") at a price of $0.37 per Share. This is a normal-course
grant that comprises part of the long-term compensation and
employee retention incentives program provided by the Corporation.
Options will vest in three equal twelve (12) month installments
commencing on January 17, 2026, with all of the Options
expiring on January 17, 2035.
ABOUT LSL PHARMA GROUP INC.
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical
company specializing in the development, manufacturing, and
commercialization of high-quality sterile ophthalmic
pharmaceuticals, as well as natural health products in solid,
semi-solid and liquid dosage forms. For further information, please
visit www.groupelslpharma.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) have reviewed or accept responsibility for the
adequacy or accuracy of this release.
SOURCE Groupe LSL PHARMA INC.
